The Polycythemia Vera Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Polycythemia Vera Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Polycythemia Vera Market.
Some of the key takeaways from the Polycythemia Vera Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Polycythemia Vera treatment therapies with a considerable amount of success over the years.
-
Polycythemia Vera companies working in the treatment market are Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist Therapeutics, Inc., Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others, are developing therapies for the Polycythemia Vera treatment
-
Emerging Polycythemia Vera therapies in the different phases of clinical trials are- Rusfertide (PTG-300), Givinostat (ITF2357), Bomedemstat, SLN124, Sapablursen, PPMX-T003, PTG-300, SLN124, Hydroxyurea, Ropeginterferon alfa-2b, PEG-P-INF alpha-2b (P1101), Ruxolitinib, and others are expected to have a significant impact on the Polycythemia Vera market in the coming years.
-
In June 2024, AOP Orphan Pharmaceuticals GmbH (AOP Health) continues its successful hematology/oncology clinical research program with two abstracts accepted for presentation at the European Hematology Association (EHA) 2024 hybrid congress in Madrid, Spain. One abstract includes an oral presentation of the latest findings from the PROUD-PV and CONTINUATION-PV trials. The results demonstrate a link between genetic changes (molecular response) and event-free survival (EFS) in polycythemia vera (PV) patients treated with ropeginterferon alfa-2b (BESREMi®) or the best available treatment.
-
In February 2024, Disc Medicine has disclosed that the US FDA has awarded Orphan Drug Designation to DISC-3405 for treating patients with PV. Additionally, in September 2023, the FDA granted fast track designation to MWTX-003, also known as DISC-3405, for PV treatment.
-
In January 2024, Takeda and Protagonist Therapeutics have established a global licensing and collaboration agreement for rusfertide.
-
In September 2023, NICE has endorsed Novartis’s JAKAVI (ruxolitinib) for individuals diagnosed with PV.
Polycythemia Vera Overview
Polycythemia vera (PV) is a rare blood disorder characterized by the overproduction of red blood cells in the bone marrow. This overproduction leads to thickening of the blood, which can slow its flow and increase the risk of clotting.
Get a Free Sample PDF Report to know more about Polycythemia Vera Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/polycythemia-vera-pipeline-insight
Emerging Polycythemia Vera Drugs Under Different Phases of Clinical Development Include:
-
Rusfertide (PTG-300): Protagonist Therapeutics
-
Givinostat (ITF2357): Italfarmaco
-
Bomedemstat: Imago BioSciences
-
SLN124: Silence Therapeutics
-
Sapablursen: Ionis Pharmaceutical
-
PPMX-T003: Perseus Proteomics
-
PTG-300: Protagonist Therapeutics, Inc.
-
SLN124: Silence Therapeutics plc
-
Hydroxyurea: Novartis
-
Ropeginterferon alfa-2b: PharmaEssentia
-
PEG-P-INF alpha-2b (P1101): AOP Orphan Pharmaceuticals AG
-
Ruxolitinib: Incyte Corporation
Polycythemia Vera Route of Administration
Polycythemia Vera pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Polycythemia Vera Molecule Type
Polycythemia Vera Products have been categorized under various Molecule types, such as
-
Oligonucleotide
-
Peptide
-
Small molecule
Polycythemia Vera Pipeline Therapeutics Assessment
-
Polycythemia Vera Assessment by Product Type
-
Polycythemia Vera By Stage and Product Type
-
Polycythemia Vera Assessment by Route of Administration
-
Polycythemia Vera By Stage and Route of Administration
-
Polycythemia Vera Assessment by Molecule Type
-
Polycythemia Vera by Stage and Molecule Type
DelveInsight’s Polycythemia Vera Report covers around 10+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Polycythemia Vera product details are provided in the report. Download the Polycythemia Vera pipeline report to learn more about the emerging Polycythemia Vera therapies
Some of the key companies in the Polycythemia Vera Therapeutics Market include:
Key companies developing therapies for Polycythemia Vera are – F. Hoffmann-La Roche Ltd, Fujifilm Holdings Corp, Hangzhou Bensheng Pharmaceutical Co Ltd, Protagonist Therapeutics Inc, Ascentage Pharma Group International, Imago BioSciences Inc, and Ionis Pharmaceuticals Inc, and others.
Polycythemia Vera Pipeline Analysis:
The Polycythemia Vera pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Polycythemia Vera with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Polycythemia Vera Treatment.
-
Polycythemia Vera key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Polycythemia Vera Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Polycythemia Vera market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Polycythemia Vera drugs and therapies
Polycythemia Vera Pipeline Market Strengths
-
The approval of BESREMi in the US and its expected approval in Japan, in both the first and second line of treatment, provides the interferon with an immense opportunity to garner a big market size in Polycythemia Vera.
-
Based on increasing sales of JAKAFI/JAKAVI, the drug will be a blockbuster therapy in 2L PV patients
Polycythemia Vera Pipeline Market Opportunities
-
An increase in strategic alliances, such as geographical alliances, and granting the designation such as BTD and FTD by the FDA are some of the factors that will drive the market growth.
-
Opportunity for drugs with novel and disease-modifying mechanisms and low side effect.
Scope of Polycythemia Vera Pipeline Drug Insight
-
Coverage: Global
-
Key Polycythemia Vera Companies: Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist Therapeutics, Inc., Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others
-
Key Polycythemia Vera Therapies: Rusfertide (PTG-300), Givinostat (ITF2357), Bomedemstat, SLN124, Sapablursen, PPMX-T003, PTG-300, SLN124, Hydroxyurea, Ropeginterferon alfa-2b, PEG-P-INF alpha-2b (P1101), Ruxolitinib, and others
-
Polycythemia Vera Therapeutic Assessment: Polycythemia Vera current marketed and Polycythemia Vera emerging therapies
-
Polycythemia Vera Market Dynamics: Polycythemia Vera market drivers and Polycythemia Vera market barriers
Request for Sample PDF Report for Polycythemia Vera Pipeline Assessment and clinical trials
Table of Contents
1. Polycythemia Vera Report Introduction
2. Polycythemia Vera Executive Summary
3. Polycythemia Vera Overview
4. Polycythemia Vera- Analytical Perspective In-depth Commercial Assessment
5. Polycythemia Vera Pipeline Therapeutics
6. Polycythemia Vera Late Stage Products (Phase II/III)
7. Polycythemia Vera Mid Stage Products (Phase II)
8. Polycythemia Vera Early Stage Products (Phase I)
9. Polycythemia Vera Preclinical Stage Products
10. Polycythemia Vera Therapeutics Assessment
11. Polycythemia Vera Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Polycythemia Vera Key Companies
14. Polycythemia Vera Key Products
15. Polycythemia Vera Unmet Needs
16 . Polycythemia Vera Market Drivers and Barriers
17. Polycythemia Vera Future Perspectives and Conclusion
18. Polycythemia Vera Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/